Here are four notes:
1. Researchers studied the use of the vaccine in mice, which laid the groundwork for a single treatment against various “alpha viruses” such as Chikungunya virus.
2. Lead researcher, Michael Diamond, MD, and his colleagues studied mosquito-borne viruses that usually cause only sporadic outbreaks.
3. After screening 60 antibodies against Chikungunya, researchers found 10 antibodies reacted against three or more different viruses that cause arthritis-like symptoms.
4. The National Institute of Health, in part, funded the study.
Dr. Diamond said, “We have more work to do but are encouraged that [this] could be a viable strategy for developing vaccines or treatments against Chikungunya and other related viruses that cause significant disease worldwide.”
More articles on quality & infection control:
Can too much foot traffic in the OR affect patient safety? Study says yes — 5 insights
Copper can help prevent the spread of respiratory viruses, study finds — 5 highlights
68k Texas residents gain access to quality healthcare — 5 notes
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
